COVID-19 Coagulopathy: An Evolving Story

Lancet Haematol. 2020 Jun;7(6):e425. doi: 10.1016/S2352-3026(20)30151-4.

Publication types

  • Editorial

MeSH terms

  • Anticoagulants / therapeutic use
  • Antiviral Agents / therapeutic use
  • Betacoronavirus / drug effects
  • Betacoronavirus / isolation & purification
  • Blood Coagulation* / drug effects
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Critical Illness
  • Disseminated Intravascular Coagulation / blood
  • Disseminated Intravascular Coagulation / drug therapy
  • Disseminated Intravascular Coagulation / etiology*
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Inflammation / blood
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Pandemics
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Thromboembolism / blood
  • Thromboembolism / drug therapy
  • Thromboembolism / etiology
  • Thrombosis / blood
  • Thrombosis / drug therapy
  • Thrombosis / etiology*

Substances

  • Anticoagulants
  • Antiviral Agents
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2